- Home
- MKSI vs XOMAO Comparison
MKSI vs XOMAO Comparison
Compare MKSI & XOMAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKSI
- XOMAO
- Stock Information
- Founded
- MKSI 1961
- XOMAO N/A
- Country
- MKSI United States
- XOMAO United States
- Employees
- MKSI N/A
- XOMAO 13
- Industry
- MKSI Industrial Machinery/Components
- XOMAO Biotechnology: Pharmaceutical Preparations
- Sector
- MKSI Industrials
- XOMAO Health Care
- Exchange
- MKSI Nasdaq
- XOMAO Nasdaq
- Market Cap
- MKSI N/A
- XOMAO N/A
- IPO Year
- MKSI 1999
- XOMAO N/A
- Fundamental
- Price
- MKSI $103.53
- XOMAO $25.55
- Analyst Decision
- MKSI Buy
- XOMAO
- Analyst Count
- MKSI 11
- XOMAO 0
- Target Price
- MKSI $142.09
- XOMAO N/A
- AVG Volume (30 Days)
- MKSI 759.7K
- XOMAO N/A
- Earning Date
- MKSI 02-05-2025
- XOMAO N/A
- Dividend Yield
- MKSI 0.85%
- XOMAO N/A
- EPS Growth
- MKSI N/A
- XOMAO N/A
- EPS
- MKSI 0.45
- XOMAO N/A
- Revenue
- MKSI $3,544,000,000.00
- XOMAO N/A
- Revenue This Year
- MKSI $0.41
- XOMAO N/A
- Revenue Next Year
- MKSI $8.80
- XOMAO N/A
- P/E Ratio
- MKSI $231.56
- XOMAO N/A
- Revenue Growth
- MKSI N/A
- XOMAO N/A
- 52 Week Low
- MKSI $95.71
- XOMAO N/A
- 52 Week High
- MKSI $147.40
- XOMAO N/A
- Technical
- Relative Strength Index (RSI)
- MKSI 37.41
- XOMAO 52.86
- Support Level
- MKSI $111.63
- XOMAO $25.31
- Resistance Level
- MKSI $112.71
- XOMAO $25.69
- Average True Range (ATR)
- MKSI 3.85
- XOMAO 0.10
- MACD
- MKSI -1.55
- XOMAO 0.03
- Stochastic Oscillator
- MKSI 13.27
- XOMAO 61.70
About XOMAO AGNC Investment Corp.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.